{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T11:22:05Z","timestamp":1772882525693,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,9,19]],"date-time":"2014-09-19T00:00:00Z","timestamp":1411084800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s10549-014-3136-y","type":"journal-article","created":{"date-parts":[[2014,9,18]],"date-time":"2014-09-18T05:59:54Z","timestamp":1411019994000},"page":"551-555","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status in invasive breast cancer: a 3,198 cases study at National Cancer Center, China"],"prefix":"10.1007","volume":"147","author":[{"given":"Xinxin","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianming","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,9,19]]},"reference":[{"issue":"Suppl 4","key":"3136_CR1","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1186\/bcr2737","volume":"12","author":"SN Akarolo-Anthony","year":"2010","unstructured":"Akarolo-Anthony SN, Ogundiran TO, Adebamowo CA (2010) Emerging breast cancer epidemic: evidence from Africa. Breast Cancer Res 12(Suppl 4):S8","journal-title":"Breast Cancer Res"},{"issue":"1","key":"3136_CR2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4103\/0973-1482.131414","volume":"10","author":"R Singh","year":"2014","unstructured":"Singh R, Gupta S, Pawar SB, Pawar RS, Gandham SV, Prabhudesai S (2014) Evaluation of ER, PR and HER-2 receptor expression in breast cancer patients presenting to a semi urban cancer centre in Western India. J Cancer Res Ther 10(1):26\u201328","journal-title":"J Cancer Res Ther"},{"issue":"5","key":"3136_CR3","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.1999.17.5.1474","volume":"17","author":"JM Harvey","year":"1999","unstructured":"Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17(5):1474\u20131481","journal-title":"J Clin Oncol"},{"key":"3136_CR4","doi-asserted-by":"crossref","unstructured":"Raji A, Lurie RH (2007) Human epidermal growth factor receptor 2 testing recommendation. Arch Pathol Lab Med 131(9):1330\u20131331; author reply 1331\u20131333","DOI":"10.1200\/JCO.2007.11.7580"},{"key":"3136_CR5","first-page":"494581","volume":"2014","author":"XL Zhou","year":"2014","unstructured":"Zhou XL, Fan W, Yang G, Yu MX (2014) The clinical significance of PR, ER, NF-kappa B, and TNF-alpha in breast cancer. Dis Markers 2014:494581","journal-title":"Dis Markers"},{"issue":"21","key":"3136_CR6","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","volume":"295","author":"LA Carey","year":"2006","unstructured":"Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492\u20132502","journal-title":"JAMA"},{"issue":"29","key":"3136_CR7","doi-asserted-by":"crossref","first-page":"7350","DOI":"10.1200\/JCO.2005.03.3845","volume":"23","author":"JD Brenton","year":"2005","unstructured":"Brenton JD, Carey LA, Ahmed AA, Caldas C (2005) Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23(29):7350\u20137360","journal-title":"J Clin Oncol"},{"issue":"6","key":"3136_CR8","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1524-4741.2009.00822.x","volume":"15","author":"CA Parise","year":"2009","unstructured":"Parise CA, Bauer KR, Brown MM, Caggiano V (2009) Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999\u20132004. Breast J 15(6):593\u2013602","journal-title":"Breast J"},{"issue":"3","key":"3136_CR9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000315039","volume":"5","author":"S Karger","year":"2010","unstructured":"Karger S, Freiburg GH (2010) Pathologists\u2019 guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Breast Care (Basel) 5(3):185\u2013187","journal-title":"Breast Care (Basel)"},{"issue":"10","key":"3136_CR10","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1158\/1055-9965.1558.13.10","volume":"13","author":"MD Althuis","year":"2004","unstructured":"Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME (2004) Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomark Prev 13(10):1558\u20131568","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"10","key":"3136_CR11","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2003.09.099","volume":"21","author":"VJ Bardou","year":"2003","unstructured":"Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM (2003) Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21(10):1973\u20131979","journal-title":"J Clin Oncol"},{"issue":"4717","key":"3136_CR12","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.2992089","volume":"229","author":"CR King","year":"1985","unstructured":"King CR, Kraus MH, Aaronson SA (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229(4717):974\u2013976","journal-title":"Science"},{"issue":"4785","key":"3136_CR13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235(4785):177\u2013182","journal-title":"Science"},{"issue":"Suppl 3","key":"3136_CR14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.9-suppl_3-4","volume":"9","author":"FJ Esteva","year":"2004","unstructured":"Esteva FJ (2004) Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer. Oncologist 9(Suppl 3):4\u20139","journal-title":"Oncologist"},{"key":"3136_CR15","doi-asserted-by":"crossref","unstructured":"Singh JC, Jhaveri K, Esteva FJ (2014) HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development. Br J Cancer","DOI":"10.1038\/bjc.2014.388"},{"issue":"3","key":"3136_CR16","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2559.2011.03883.x","volume":"59","author":"MB Satti","year":"2011","unstructured":"Satti MB (2011) Oestrogen receptor\/progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer: a 9-year study at Princess Noorah Oncology Center Saudi Arabia. Histopathol 59(3):537\u2013542","journal-title":"Histopathol"},{"issue":"4","key":"3136_CR17","first-page":"337","volume":"4","author":"M Singh","year":"2014","unstructured":"Singh M, Ding Y, Zhang LY, Song D, Gong Y, Adams S, Ross DS, Wang JH, Grover S, Doval DC et al (2014) Distinct breast cancer subtypes in women with early-onset disease across races. Am J Cancer Res 4(4):337\u2013352","journal-title":"Am J Cancer Res"},{"key":"3136_CR18","doi-asserted-by":"crossref","unstructured":"Cui Y, Deming-Halverson SL, Shrubsole MJ, Beeghly-Fadiel A, Fair AM, Sanderson M, Shu XO, Kelley MC, Zheng W (2014) Associations of hormone-related factors with breast cancer risk according to hormone receptor status among white and african american women. Clin Breast Cancer","DOI":"10.1016\/j.clbc.2014.04.003"},{"issue":"1","key":"3136_CR19","doi-asserted-by":"crossref","first-page":"R9","DOI":"10.1186\/bcr2225","volume":"11","author":"JA Zell","year":"2009","unstructured":"Zell JA, Tsang WY, Taylor TH, Mehta RS, Anton-Culver H (2009) Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry. Breast Cancer Res 11(1):R9","journal-title":"Breast Cancer Res"},{"issue":"19","key":"3136_CR20","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","volume":"98","author":"T Sorlie","year":"2001","unstructured":"Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869\u201310874","journal-title":"Proc Natl Acad Sci USA"},{"key":"3136_CR21","doi-asserted-by":"crossref","unstructured":"Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA (2014) Subtyping of triple-negative breast cancer: implications for therapy. Cancer","DOI":"10.1002\/cncr.28914"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-014-3136-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-014-3136-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-014-3136-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,16]],"date-time":"2023-07-16T16:47:37Z","timestamp":1689526057000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-014-3136-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,19]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["3136"],"URL":"https:\/\/doi.org\/10.1007\/s10549-014-3136-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,19]]}}}